MIRUM PHARMACEUTICALS INC (MIRM) — insider trading
Health Care · NASDAQ
MIRUM PHARMACEUTICALS INC (MIRM) has 28 reported SEC Form 4 insider transactions in our data, including 10 open-market sales among the most recent 28 (latest 2026-07-06).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-06 | BJERKHOLT ERIC | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 300 | $124.94 | $37.5K | Form 4 |
| 2026-07-06 | BJERKHOLT ERIC | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 528 | $123.84 | $65.4K | Form 4 |
| 2026-07-06 | BJERKHOLT ERIC | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 1,048 | $122.43 | $128.3K | Form 4 |
| 2026-07-06 | BJERKHOLT ERIC | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 3,124 | $121.67 | $380.1K | Form 4 |
| 2026-07-06 | Peetz Christopher | Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise / conversion (derivative) | 20,000 | $0.00 | $0 | Form 4 |
| 2026-07-06 | Peetz Christopher | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 1,710 | $124.79 | $213.4K | Form 4 |
| 2026-07-06 | Peetz Christopher | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 1,975 | $123.74 | $244.4K | Form 4 |
| 2026-07-06 | Peetz Christopher | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 4,181 | $122.34 | $511.5K | Form 4 |
| 2026-07-06 | Peetz Christopher | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 12,134 | $121.65 | $1.48M | Form 4 |
| 2026-07-06 | Peetz Christopher | Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise / conversion | 20,000 | $2.94 | $58.7K | Form 4 |
| 2026-07-01 | Howe Jolanda | Officer (SVP, GLOBAL CONTROLLER) | Open-market sale | 2,721 | $120.00 | $326.5K | Form 4 |
| 2026-06-17 | Howe Jolanda | Officer (SVP, GLOBAL CONTROLLER) | Open-market sale | 2,594 | $101.95 | $264.5K | Form 4 |
| 2026-06-15 | GREY MICHAEL G | Director | Grant / award / vesting (derivative) | 1,980 | $0.00 | $0 | Form 4 |
| 2026-06-15 | GREY MICHAEL G | Director | Grant / award / vesting (derivative) | 3,772 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Fischer Laurent | Director | Grant / award / vesting (derivative) | 1,980 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Fischer Laurent | Director | Grant / award / vesting (derivative) | 3,772 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Heron Patrick J | Director | Grant / award / vesting (derivative) | 1,980 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Heron Patrick J | Director | Grant / award / vesting (derivative) | 3,772 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Brege Laura | Director | Grant / award / vesting (derivative) | 1,980 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Brege Laura | Director | Grant / award / vesting (derivative) | 3,772 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Fairey William | Director | Grant / award / vesting (derivative) | 1,980 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Fairey William | Director | Grant / award / vesting (derivative) | 3,772 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Ramasastry Saira | Director | Grant / award / vesting (derivative) | 1,980 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Ramasastry Saira | Director | Grant / award / vesting (derivative) | 3,772 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Cardon Lon | Director | Grant / award / vesting (derivative) | 1,980 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Cardon Lon | Director | Grant / award / vesting (derivative) | 3,772 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Walbert Timothy P | Director | Grant / award / vesting (derivative) | 1,980 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Walbert Timothy P | Director | Grant / award / vesting (derivative) | 3,772 | $0.00 | $0 | Form 4 |
Ask the chat about MIRM's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: MIRUM PHARMACEUTICALS INC (MIRM).
Last updated 2026-07-06 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.